Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Eb613 symbols : AMGN save search
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
Published: 2023-02-15 (Crawled : 15:20) - globenewswire.com
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 2.34%
H: 9.2%
C: 8.45%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.34%
H: 0.14%
C: -0.06%
eb613 treatment meeting review osteoporosis
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement osteoporosis
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis- Total Hip BMD Established as Primary Endpoint -
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
Published: 2022-09-21 (Crawled : 13:00) - biospace.com/
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 0.0%
H: 7.73%
C: 6.61%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: 0.62%
H: 0.65%
C: -2.04%
eb613 treatment impact potential osteoporosis
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
Published: 2022-09-12 (Crawled : 11:00) - globenewswire.com
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 0.72%
H: 6.43%
C: 0.0%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
eb613 correlation meeting response study osteoporosis
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 613
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published: 2022-01-04 (Crawled : 14:00) - globenewswire.com
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 bone 613 spine phase 3
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - globenewswire.com
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 0.82%
H: 5.26%
C: 4.88%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: 0.01%
H: 0.25%
C: -0.98%
presentation phase 2 osteoporosis eb613
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
Published: 2021-08-02 (Crawled : 13:15) - biospace.com/
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 5.4%
H: 2.66%
C: 1.71%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.37%
H: 0.15%
C: -0.96%
treatment phase 2 bone eb613 research osteoporosis
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
Published: 2021-06-28 (Crawled : 20:00) - globenewswire.com
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: -0.66%
H: 0.36%
C: -4.15%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
treatment phase 2 bone phase 2 results results eb613 conference osteoporosis
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
Published: 2021-06-23 (Crawled : 13:00) - globenewswire.com
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 60.58%
H: 20.39%
C: -9.85%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.11%
H: 0.04%
C: -0.39%
phase 2 topline eb613 dmd
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
UMAC | $1.55 0.65% 12.9% 0
|
TAOP | $1.08 13.01% 11.51% 19K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.